ClinicalTrials.gg
CompletedNCT03029780CheckMate 800Updated Jun 29, 2022Results posted

An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma

A Phase 2 interventional study of Opdivo and Yervoy in Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb. Completed at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-29.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 64 studies testing nivolumab in Carcinoma, Renal Cell — 9 open to participants now, 23 under way, 3 of them phase 3. Nivolumab · Carcinoma, Renal Cell.

Enrollment
25th of 64
104 · median 52
Started
2017
with 12 others
Phase 2
36 of 64
6 open now
Registered
24th of 64
by date
Lead sponsor
14 of 64
Bristol-Myers Squibb

Among the 64 studies testing nivolumab in Carcinoma, Renal Cell, this one is the 25th largest by enrollment, is one of 13 that started in 2017, is one of 36 in phase 2, and was the 24th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

9 of the 64 studies testing nivolumab in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing nivolumab in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate safety and efficacy of different administration regimens of nivolumab plus ipilimumab in subjects with renal cell carcinoma.

03

Conditions studied

  • Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Advanced Renal Cell Carcinoma
  • Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work
  • Must have at least 1 lesion with

Exclusion criteria

Exclusion Criteria:

  • Subjects with active central nervous system
  • Subjects who received prior therapy with
  • Subjects with active, known or suspected disease

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Co-Administration

    Nivolumab and Ipilimumab Co-Administration

    Biological: Opdivo · Biological: Yervoy

  • Experimental
    Sequential Administration

    Nivolumab and Ipilimumab Sequential Administration

    Biological: Opdivo · Biological: Yervoy

Interventions

  • BiologicalOpdivo

    Specified dose on specified days

    Also known as: Nivolumab

  • BiologicalYervoy

    Specified dose on specified days

    Also known as: Ipilimumab

06

What researchers measure

Primary outcomes

  1. The Percentage of Participant With Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ) Within 2 Days After Any Dose in the Combination Period

    The percentage of participants who experienced at least 1 adverse event in the MedDRA Anaphylactic Reaction broad scope SMQ with onset on the day of or within 2 days after any study therapy infusion during the combination period (Part 1).

    Time frame: From randomization to 2 days following any dose in the combination period (assessed up to November 24th, 2017, approximately 9 months)

Secondary outcomes

  1. The Percentage of Participant With Adverse Events in the Narrow Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ) Occurring Within 2 Days After Any Dose in the Combination Period

    The percentage of participants who experienced at least 1 adverse event in the MedDRA Anaphylactic Reaction narrow scope SMQ with onset on the day of or within 2 days after any study therapy infusion during the combination period (Part 1).

    Time frame: From randomization to 2 days following any dose in the combination period (assessed up to November 24th, 2017, approximately 9 months)

  2. The Percentage of Participants With Drug Related Grade 3-5 Adverse Events

    The percentage of participants who experienced at least 1 adverse event of Grade 3 or higher, judged to be related to study treatment by the investigator, with onset on or after the first dose of study treatment and within 30 days of the last dose of study treatment. Evaluated using Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria.

    Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 48 months)

  3. The Percentage of Participants With All Causality Grade 3-5 Adverse Events

    The percentage of participants who experienced at least 1 adverse event of Grade 3 or higher with onset on or after the first dose of study treatment and within 30 days of the last dose of study treatment. Evaluated using the NCI CTCAE version 4.0 criteria

    Time frame: From first dose to 30 days after last dose of study therapy (up to approximately 48 months)

  4. Objective Response Rate (ORR)

    The percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). The BOR is defined as the best response designation, as determined by the investigator, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of first subsequent anti-cancer therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR assessment. Complete Response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10mm. Partial Response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From randomization to the date of objectively documented progression or the date of first subsequent anti-cancer (up to approximately 52 months)

  5. Progression Free Survival (PFS)

    The time between the date of randomization and the first date of documented progression, or death due to any cause, whichever occurs first (per investigator). Participants who die without progression will be considered to have progressed on the date of their death. Participants who did not progress or die are censored on the date of their last evaluable tumor assessment. Participants with no on study tumor assessments and who did not die will be censored on their date of randomization. Participants who started anti-cancer therapy without a prior reported progression will be censored on the date of their last evaluable tumor assessment prior to the first subsequent anti-cancer therapy. Progression is defined as at least a 20% increase in the sum of diameters of target lesions. The sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression)

    Time frame: From randomization to the first date of documented progression or death due to any cause (up to approximately 52 months)

  6. Geometric Mean Trough Concentrations of Nivolumab and Ipilimumab

    Serum concentration-time data of nivolumab and ipilimumab administered as a fixed ratio combination to that of sequentially administered nivolumab and ipilimumab is summarized prior to the next dose (predose). 1 Cycle = 3 weeks

    Time frame: pre-dose on day 1 of cycle 2 and 4

  7. Geometric Mean End of Infusion (EOI) Concentrations of Nivolumab and Ipilimumab

    Serum concentration-time data of nivolumab and ipilimumab administered as a fixed ratio combination to that of sequentially administered nivolumab and ipilimumab is summarized at the end of infusion (EOI). 1 Cycle = 3 weeks

    Time frame: EOI on day 1 of cycle 1, 2, and 4

07

Results

Posted Dec 19, 2018

Participant flow

Participant flow — Overall Study
MilestoneArm A: Fixed Ratio CombinationArm B: Sequential Combination
Started5252
Completed11
Not completed5151
Withdrew: Disease progression2022
Withdrew: Study drug toxicity1511
Withdrew: Adverse event unrelated to study drug23
Withdrew: Participant request to discontinue study treatment41
Withdrew: Maximum clinical benefit10
Withdrew: Participant no longer meets study criteria01
Withdrew: Other reasons66
Withdrew: Not reported11
Withdrew: Death26

Outcome measures

PrimaryThe Percentage of Participant With Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ) Within 2 Days After Any Dose in the Combination Period

The percentage of participants who experienced at least 1 adverse event in the MedDRA Anaphylactic Reaction broad scope SMQ with onset on the day of or within 2 days after any study therapy infusion during the combination period (Part 1).

Time frame:
From randomization to 2 days following any dose in the combination period (assessed up to November 24th, 2017, approximately 9 months)
Reported as:
Number · Percentage of Participants
The Percentage of Participant With Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ) Within 2 Days After Any Dose in the Combination Period
Percentage of ParticipantsArm A: Fixed Ratio CombinationArm B: Sequential Combination
The Percentage of Participant With Adverse Events (AEs) in the Broad Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ) Within 2 Days After Any Dose in the Combination Period11.5 (4.4 to 23.4)11.5 (4.4 to 23.4)
Statistical analysis
  • Arm A: Fixed Ratio Combination vs Arm B: Sequential Combination · Difference in incidence rates: 0.0 · 95% CI -12.3 to 12.3
  • Arm A: Fixed Ratio Combination vs Arm B: Sequential Combination · Cochran-Mantel-Haenszel · Odds ratio (or): 1.00 · 95% CI 0.30 to 3.39
SecondaryThe Percentage of Participant With Adverse Events in the Narrow Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ) Occurring Within 2 Days After Any Dose in the Combination Period

The percentage of participants who experienced at least 1 adverse event in the MedDRA Anaphylactic Reaction narrow scope SMQ with onset on the day of or within 2 days after any study therapy infusion during the combination period (Part 1).

Time frame:
From randomization to 2 days following any dose in the combination period (assessed up to November 24th, 2017, approximately 9 months)
Reported as:
Number · Percentage of Participants
The Percentage of Participant With Adverse Events in the Narrow Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ) Occurring Within 2 Days After Any Dose in the Combination Period
Percentage of ParticipantsArm A: Fixed Ratio CombinationArm B: Sequential Combination
The Percentage of Participant With Adverse Events in the Narrow Scope MedDRA Anaphylactic Reaction Standardized MedDRA Queries (SMQ) Occurring Within 2 Days After Any Dose in the Combination Period0 (0.0 to 6.8)0 (0.0 to 6.8)
Statistical analysis
  • Arm A: Fixed Ratio Combination vs Arm B: Sequential Combination · Difference in incidence rates: 0.00 · 95% CI 0.00 to 0.00
SecondaryThe Percentage of Participants With Drug Related Grade 3-5 Adverse Events

The percentage of participants who experienced at least 1 adverse event of Grade 3 or higher, judged to be related to study treatment by the investigator, with onset on or after the first dose of study treatment and within 30 days of the last dose of study treatment. Evaluated using Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria.

Time frame:
From first dose to 30 days after last dose of study therapy (up to approximately 48 months)
Reported as:
Number · Percentage of Participants
The Percentage of Participants With Drug Related Grade 3-5 Adverse Events
Percentage of ParticipantsArm A: Fixed Ratio CombinationArm B: Sequential Combination
The Percentage of Participants With Drug Related Grade 3-5 Adverse Events48.1 (34.0 to 62.4)42.3 (28.7 to 56.8)
Statistical analysis
  • Arm A: Fixed Ratio Combination vs Arm B: Sequential Combination · Difference in incidence rates: 5.8 · 95% CI -13.3 to 24.8
  • Arm A: Fixed Ratio Combination vs Arm B: Sequential Combination · Cochran-Mantel-Haenszel · Odds ratio (or): 1.27 · 95% CI 0.58 to 2.78
SecondaryThe Percentage of Participants With All Causality Grade 3-5 Adverse Events

The percentage of participants who experienced at least 1 adverse event of Grade 3 or higher with onset on or after the first dose of study treatment and within 30 days of the last dose of study treatment. Evaluated using the NCI CTCAE version 4.0 criteria

Time frame:
From first dose to 30 days after last dose of study therapy (up to approximately 48 months)
Reported as:
Number · Percentage of Particpants
The Percentage of Participants With All Causality Grade 3-5 Adverse Events
Percentage of ParticpantsArm A: Fixed Ratio CombinationArm B: Sequential Combination
The Percentage of Participants With All Causality Grade 3-5 Adverse Events73.1 (59.0 to 84.4)65.4 (50.9 to 78.0)
Statistical analysis
  • Arm A: Fixed Ratio Combination vs Arm B: Sequential Combination · Difference in incidence rates: 7.7 · 95% CI -10.1 to 25.5
  • Arm A: Fixed Ratio Combination vs Arm B: Sequential Combination · Cochran-Mantel-Haenszel · Odds ratio (or): 1.42 · 95% CI 0.62 to 3.24
SecondaryObjective Response Rate (ORR)

The percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR). The BOR is defined as the best response designation, as determined by the investigator, recorded between the date of randomization and the date of objectively documented progression per RECIST 1.1 or the date of first subsequent anti-cancer therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR assessment. Complete Response is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10mm. Partial Response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From randomization to the date of objectively documented progression or the date of first subsequent anti-cancer (up to approximately 52 months)
Reported as:
Number · Percentage of Particpants
Objective Response Rate (ORR)
Percentage of ParticpantsArm A: Fixed Ratio CombinationArm B: Sequential Combination
Objective Response Rate (ORR)50.0 (35.8 to 64.2)32.7 (20.3 to 47.1)
SecondaryProgression Free Survival (PFS)

The time between the date of randomization and the first date of documented progression, or death due to any cause, whichever occurs first (per investigator). Participants who die without progression will be considered to have progressed on the date of their death. Participants who did not progress or die are censored on the date of their last evaluable tumor assessment. Participants with no on study tumor assessments and who did not die will be censored on their date of randomization. Participants who started anti-cancer therapy without a prior reported progression will be censored on the date of their last evaluable tumor assessment prior to the first subsequent anti-cancer therapy. Progression is defined as at least a 20% increase in the sum of diameters of target lesions. The sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression)

Time frame:
From randomization to the first date of documented progression or death due to any cause (up to approximately 52 months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsArm A: Fixed Ratio CombinationArm B: Sequential Combination
Progression Free Survival (PFS)12.06 (9.92 to 18.23)7.69 (3.42 to 11.33)
SecondaryGeometric Mean Trough Concentrations of Nivolumab and Ipilimumab

Serum concentration-time data of nivolumab and ipilimumab administered as a fixed ratio combination to that of sequentially administered nivolumab and ipilimumab is summarized prior to the next dose (predose). 1 Cycle = 3 weeks

Time frame:
pre-dose on day 1 of cycle 2 and 4
Reported as:
Geometric mean · ug/mL
Geometric Mean Trough Concentrations of Nivolumab and Ipilimumab
ug/mLArm A: Fixed Ratio CombinationArm B: Sequential Combination
Ipilimumab - Cycle 2 Day 13.92 ± 28.93.43 ± 43.1
Ipilimumab - Cycle 4 Day 15.90 ± 37.85.39 ± 39.8
Nivolumab - Cycle 2 Day 116.2 ± 29.116.1 ± 46.3
Nivolumab - Cycle 4 Day 128.5 ± 35.330.5 ± 43.1
SecondaryGeometric Mean End of Infusion (EOI) Concentrations of Nivolumab and Ipilimumab

Serum concentration-time data of nivolumab and ipilimumab administered as a fixed ratio combination to that of sequentially administered nivolumab and ipilimumab is summarized at the end of infusion (EOI). 1 Cycle = 3 weeks

Time frame:
EOI on day 1 of cycle 1, 2, and 4
Reported as:
Geometric mean · ug/mL
Geometric Mean End of Infusion (EOI) Concentrations of Nivolumab and Ipilimumab
ug/mLArm A: Fixed Ratio CombinationArm B: Sequential Combination
Ipilimumab - Cycle 1 Day 117.6 ± 23.713.4 ± 61.1
Ipilimumab - Cycle 2 Day 121.4 ± 24.815.6 ± 37.9
Ipilimumab - Cycle 4 Day 124.9 ± 31.319.5 ± 38.5
Nivolumab - Cycle 1 Day 157.1 ± 22.460.7 ± 23.0
Nivolumab - Cycle 2 Day 170.6 ± 27.679.5 ± 71.9
Nivolumab - Cycle 4 Day 185.1 ± 30.188.9 ± 55.1

Adverse events

Collected over From the date of first dose to 30 days after last dose of study therapy. (up to approximately 48 months) Participants were assessed for All Cause Mortality from their first dose until the study was completed (up to approximately 52 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Fixed Ratio Combination26/52 (50%)27/52 (51.9%)49/52 (94.2%)
Arm B: Sequential Combination29/52 (55.8%)25/52 (48.1%)48/52 (92.3%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventArm A: Fixed Ratio CombinationArm B: Sequential Combination
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)5/525/52
HypophysitisEndocrine disorders0/523/52
PyrexiaGeneral disorders3/520/52
HyperglycaemiaMetabolism and nutrition disorders3/520/52
MyocarditisCardiac disorders2/520/52
Adrenocortical insufficiency acuteEndocrine disorders2/521/52
DiarrhoeaGastrointestinal disorders2/520/52
Urinary tract infectionInfections and infestations0/522/52
Acute coronary syndromeCardiac disorders0/521/52
Acute myocardial infarctionCardiac disorders0/521/52
Most frequent other events
Showing 10 of 55
Most frequent other events
EventArm A: Fixed Ratio CombinationArm B: Sequential Combination
FatigueGeneral disorders24/5215/52
RashSkin and subcutaneous tissue disorders20/5210/52
PruritusSkin and subcutaneous tissue disorders15/5215/52
Lipase increasedInvestigations14/5211/52
DiarrhoeaGastrointestinal disorders13/5211/52
HypothyroidismEndocrine disorders12/528/52
HyperglycaemiaMetabolism and nutrition disorders12/523/52
CoughRespiratory, thoracic and mediastinal disorders12/525/52
Amylase increasedInvestigations11/529/52
Blood creatinine increasedInvestigations10/5211/52

Baseline characteristics

All treated participants.

Age, Continuous
Age, Continuous(Years)Arm A: Fixed Ratio CombinationArm B: Sequential CombinationTotal
Mean62.2 ± 10.962.6 ± 9.962.4 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Fixed Ratio CombinationArm B: Sequential CombinationTotal
Female101424
Male423880
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Count of participants)Arm A: Fixed Ratio CombinationArm B: Sequential CombinationTotal
White465197
Black or African American101
Asian303
American Indian or Alaska Native000
Native Hawaiian or Other Pacific Islander101
Other112
08

Study locations

11 sites
  • Cancer Specialists of North FL
    Jacksonville, Florida 32256, United States
  • University Of Iowa Hospitals And Clinics
    Iowa City, Iowa 52242, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Local Institution
    Pittsburgh, Pennsylvania 15212-0000, United States
  • Local Institution
    Waratah, New South Wales 2298, Australia
  • Local Institution
    Westmead, New South Wales 2145, Australia
  • Local Institution
    Herston, Queensland 4029, Australia
  • Local Institution
    Elizabeth Vale, South Australia 5112, Australia
  • Local Institution
    Malvern, Victoria 3144, Australia
  • Fundacion Arturo Lopez Perez
    Santiago, Metropolitana 7500921, Chile
  • Centro Internacional de Estudios Clinicos
    Recoleta, Santiago De Chile, Chile
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Nov 2017, 9 months.

Results were first posted in Dec 2018, 1 year after primary completion.

Of 47 industry-sponsored phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's 9 months is below that.

Counting every sponsor, half of 232 studies reached it within 58 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2017
First posted
Jan 24, 2017
StartActual
Feb 16, 2017
Primary completionActual
Nov 27, 2017
CompletionActual
Jun 15, 2021
Results first posted
Dec 19, 2018
Last update
Jun 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03029780
Responsible party
Sponsor
First posted
Jan 24, 2017
Start date
Feb 16, 2017
Primary completion
Nov 27, 2017
Completion
Jun 15, 2021
Results posted
Dec 19, 2018
Last update
Jun 29, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion